RTOG

Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC

Retrieved on: 
Wednesday, June 29, 2022
Annual report, Patient, CEO, GLOBE, COVID-19, Population, Failure, Ownership, Cancer, Progression-free survival, U.S. Securities and Exchange Commission, RTOG, Metastasis, NSCLC, Lung cancer, GC4419, Pancreatic cancer, Literature, Therapy, Overalls, SBRT, Privacy, Radiation, Neoplasm, Private Securities Litigation Reform Act, Fatigue, Nasdaq, Health, SEC, Large-cell lung carcinoma, Safety, Cough, Nausea, Pharmaceutical industry, Medical imaging

MALVERN, Pa., June 29, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced results from the open-label Phase 1 stage of the GRECO-1 trial of rucosopasem in combination with stereotactic body radiation therapy (SBRT) in patients with centrally located or large non-small cell lung cancer (NSCLC). Enrollment is ongoing in the randomized, double-blinded, placebo-controlled Phase 2 stage of the trial, with completion of enrollment anticipated in the second half of 2023.

Key Points: 
  • The initial results from the Phase 1 stage of GRECO-1 demonstrate a promising safety profile for the rucosopasem and SBRT combination in patients with NSCLC, said Mel Sorensen, M.D., Galeras President and CEO.
  • We look forward to seeing how the combination performs compared to SBRT alone in the ongoing Phase 2 stage of this trial.
  • The primary endpoint of the Phase 2 stage of the trial is in-field (i.e., SBRT target) tumor response at six months post SBRT.
  • Patients are also being followed for long-term anti-cancer endpoints and safety similar to the Phase 1 stage of the trial.

Clinical Value of MRIdian® MRI-Guided Radiation Therapy in the Treatment of Ultracentral/Central Lung Tumors Presented at ESTRO 2022

Retrieved on: 
Tuesday, May 10, 2022
COVID-19, European Society for Medical Oncology, U.S. Securities and Exchange Commission, Bed, Esophagus, Private Securities Litigation Reform Act, Nasdaq, Toxicity, Fatigue, Company, Death, MS, Physician, H. Lee Moffitt Cancer Center & Research Institute, Radiation, Irritation, Patient, Security (finance), Thorax, Annual report, Field line, Industry, Hospital, 2021 Essex County Council election, Stereotactic surgery, Skin, Magnetic resonance imaging, Radiation therapy, Metastasis, RTOG, SEC, Hair loss, Research, Toxic leukoencephalopathy, SBRT, Cancer, Annual general meeting, Nausea, Risk, Medical imaging, MD

CLEVELAND, May 10, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today the results of a study presented at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO) titled, "MR-guided SBRT/Hypofractionated RT for Metastatic and Primary Ultracentral and Central Lung Lesions," which demonstrated that the real-time image-guidance, small treatment margins and adaptation afforded by MRIdian SMART (Stereotactic MRI-Guided Adaptive Radiotherapy) may allow for ablative radiation with minimal toxicity in ultracentral/central lung lesions.

Key Points: 
  • Prior studies of stereotactic body radiation therapy (SBRT) for ultracentral and central lung lesions have reported high rates of toxicity, including reports of fatal Grade 5 toxicities.
  • Last year the HILUS-trial, a prospective Nordic multi-center phase II study of ultracentral lung, which was conducted using non-MRI-guided radiation therapy systems, observed unacceptable high-grade toxicity when delivering SBRT to ultracentral lung tumors.
  • The trial noted Grade 3-5 toxicity in 22 of the 65 patients, including 10 cases of treatment related death.
  • ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian MRI-Guided Radiation Therapy System.

Dr. Volker W. Stieber, MD, Joins Vivacitas' Neuro-Oncology Advisory Board

Retrieved on: 
Monday, February 7, 2022
Linda, GLOBE, Assistant, Toxicity, Society, EVP, Hotel manager, Vivacitas, Berkeley, Stereotactic radiation therapy, Mayo Clinic, Research, Poster, SNO, Medical school, Medical University of South Carolina, Therapy, Wake Forest University, MD, RTOG, Pakistan Society of Neuro-Oncology, Neuro-Oncology (journal), Radiation therapy, CNS, Clinical trial, Patient, Review, Pharmacokinetics, Coronavirus Scientific Advisory Board (Turkey), LP, THE, Radiation, Drug development, IRB, Clinical professor, NRG, Glioblastoma, University, Novant Health Forsyth Medical Center, IAG, Medicine, Medical imaging, Pharmaceutical industry, Amgen

His research interests involve Neuro-Oncology clinical care, Stereotactic Radiation Therapy (CNS and Body), radiation safety and clinical trial design and review.

Key Points: 
  • His research interests involve Neuro-Oncology clinical care, Stereotactic Radiation Therapy (CNS and Body), radiation safety and clinical trial design and review.
  • Dr. Stieber stated, "Based on our team's early clinical trial experience with AR-67, I am excited about the Vivacitas pipeline of therapeutics.
  • It is a privilege to be given the opportunity to provide collaborative input as part of the Scientific Advisory Board."
  • "We are very honored and pleased that Dr. Stieber has joined our Neuro-Oncology Advisory Board.

DCISionRT® Demonstrates 40 Percent Change in Radiation Therapy Treatment Recommendation for DCIS Patients

Retrieved on: 
Thursday, December 2, 2021
Patient, Risk assessment, National, CEO, Technology, Biomarker, Company, Biology, University of California, San Francisco, Diagnosis, Woman, Precision medicine, Breast, University, Molecular biology, National Cancer Institute, Breast cancer, Database, RTOG, Physician, DCIS, Twitter, Research, Risk, TME, RT, Instagram, Ductal carcinoma, Interim, Poster, Paced Auditory Serial Addition Test, LinkedIn, FACS, Pharmaceutical industry, Medical imaging

PreludeDx will present scientific data demonstrating a significant (40%) change in radiation therapy (RT) treatment recommendations when using the DCISionRTtest.

Key Points: 
  • PreludeDx will present scientific data demonstrating a significant (40%) change in radiation therapy (RT) treatment recommendations when using the DCISionRTtest.
  • The poster is entitled, Interim analysis of the PREDICT Registry: Changes in treatment recommendation for a biologic signature predictive of radiation therapy (RT) benefit in patients with DCIS.
  • "When routinely implemented in practice, DCISionRT has the ability to successfully prevent over- or under- treatment of DCIS patients."
  • DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit.

Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy

Retrieved on: 
Tuesday, September 14, 2021
Research, Medical Devices, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Prostate, Idiopathic pulmonary fibrosis, Thyroid cancer, Man, NCCN, Journal of the National Comprehensive Cancer Network, Health, Form 10-Q, Technology, Forward-looking statement, Prostate cancer, Investor, NanoString Technologies, Patient, Cohort study, Metastasis, Kidney, Risk, RTOG, National Cancer Institute, Annual report, Physician, Breast cancer, Cancer, Twitter, Randomized controlled trial, Lung cancer, Diagnosis, SEC, Bladder cancer, Medical imaging, Pharmaceutical industry, Decipher Prostate, Veracyte, DECIPHER PROSTATE, VERACYTE

(Nasdaq: VCYT) today announced that its Decipher Prostate RP genomic classifier is uniquely recommended in the 2022 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Oncology to guide treatment decisions for men with prostate cancer.

Key Points: 
  • (Nasdaq: VCYT) today announced that its Decipher Prostate RP genomic classifier is uniquely recommended in the 2022 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Oncology to guide treatment decisions for men with prostate cancer.
  • The NCCNs designation is unique to Decipher Prostate RP and underscores the extensive clinical validation and clinical utility data behind the test.
  • We believe this recommendation will ultimately enable more men to receive the treatment they need, while reducing unnecessary therapy.
  • Decipher Prostate (Decipher Prostate Biopsy and Decipher Prostate RP) is a 22-gene, whole-transcriptome-developed genomic test intended to help inform treatment decisions for men with localized prostate cancer at initial diagnosis and after surgical removal of the prostate.